Search

Your search keyword '"Prudden, H.J."' showing total 3 results
Start Over Author "Prudden, H.J."
3 results on '"Prudden, H.J."'

2. Meeting Report: WHO Workshop on modelling global mortality and aetiology estimates of enteric pathogens in children under five. Cape Town, 28–29th November 2018

Author

Prudden, H.J., primary, Hasso-Agopsowicz, M., additional, Black, R.E., additional, Troeger, C., additional, Reiner, R.C., additional, Breiman, R.F., additional, Jit, M., additional, Kang, G., additional, Lamberti, L., additional, Lanata, C.F., additional, Lopman, B.A., additional, Ndifon, W., additional, Pitzer, V.E., additional, Platts-Mills, J.A., additional, Riddle, M.S., additional, Smith, P.G., additional, Hutubessy, R., additional, and Giersing, B., additional

Published
2020
Full Text
View/download PDF

3. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

Author

Eaton, J.W., Menzies, N.A., Stover, J., Cambiano, V., Chindelevitch, L., Cori, A., Hontelez, J.A., Humair, S., Kerr, C.C., Klein, D.J., Mishra, S., Mitchell, K.M., Nichols, B.E., Vickerman, P., Bakker, R, Barnighausen, T., Bershteyn, A., Bloom, D.E., Boily, M.C., Chang, S.T., Cohen, T., Dodd, P.J., Fraser, C., Gopalappa, C., Lundgren, J., Martin, N.K., Mikkelsen, E., Mountain, E., Pham, Q.D., Pickles, M., Phillips, A., Platt, L., Pretorius, C., Prudden, H.J., Salomon, J.A., Vijver, D.A. van de, Vlas, S.J. de, Wagner, B.G., White, R.G., Wilson, D.P., Zhang, L., Blandford, J., Meyer-Rath, G., Remme, M., Revill, P., Sangrujee, N., Terris-Prestholt, F., Doherty, M., Shaffer, N., Easterbrook, P.J., Hirnschall, G., Hallett, T.B., Eaton, J.W., Menzies, N.A., Stover, J., Cambiano, V., Chindelevitch, L., Cori, A., Hontelez, J.A., Humair, S., Kerr, C.C., Klein, D.J., Mishra, S., Mitchell, K.M., Nichols, B.E., Vickerman, P., Bakker, R, Barnighausen, T., Bershteyn, A., Bloom, D.E., Boily, M.C., Chang, S.T., Cohen, T., Dodd, P.J., Fraser, C., Gopalappa, C., Lundgren, J., Martin, N.K., Mikkelsen, E., Mountain, E., Pham, Q.D., Pickles, M., Phillips, A., Platt, L., Pretorius, C., Prudden, H.J., Salomon, J.A., Vijver, D.A. van de, Vlas, S.J. de, Wagner, B.G., White, R.G., Wilson, D.P., Zhang, L., Blandford, J., Meyer-Rath, G., Remme, M., Revill, P., Sangrujee, N., Terris-Prestholt, F., Doherty, M., Shaffer, N., Easterbrook, P.J., Hirnschall, G., and Hallett, T.B.

Abstract

Contains fulltext : 138145.pdf (publisher's version ) (Open Access), BACKGROUND: New WHO guidelines recommend initiation of antiretroviral therapy for HIV-positive adults with CD4 counts of 500 cells per muL or less, a higher threshold than was previously recommended. Country decision makers have to decide whether to further expand eligibility for antiretroviral therapy accordingly. We aimed to assess the potential health benefits, costs, and cost-effectiveness of various eligibility criteria for adult antiretroviral therapy and expanded treatment coverage. METHODS: We used several independent mathematical models in four settings-South Africa (generalised epidemic, moderate antiretroviral therapy coverage), Zambia (generalised epidemic, high antiretroviral therapy coverage), India (concentrated epidemic, moderate antiretroviral therapy coverage), and Vietnam (concentrated epidemic, low antiretroviral therapy coverage)-to assess the potential health benefits, costs, and cost-effectiveness of various eligibility criteria for adult antiretroviral therapy under scenarios of existing and expanded treatment coverage, with results projected over 20 years. Analyses assessed the extension of eligibility to include individuals with CD4 counts of 500 cells per muL or less, or all HIV-positive adults, compared with the previous (2010) recommendation of initiation with CD4 counts of 350 cells per muL or less. We assessed costs from a health-system perspective, and calculated the incremental cost (in US$) per disability-adjusted life-year (DALY) averted to compare competing strategies. Strategies were regarded very cost effective if the cost per DALY averted was less than the country's 2012 per-head gross domestic product (GDP; South Africa: $8040; Zambia: $1425; India: $1489; Vietnam: $1407) and cost effective if the cost per DALY averted was less than three times the per-head GDP. FINDINGS: In South Africa, the cost per DALY averted of extending eligibility for antiretroviral therapy to adult patients with CD4 counts of 500 cells per muL or less

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results